NeuroVive Pharmaceutical AB (publ): report from AGM
NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 30 March 2015. A summary of the resolutions follows. All resolutions were passed with the required majority.
Press releases
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Monday, 30 March 2015 at Medicon Vil ...
OnCore Biopharma and Tekmira Pharmaceuticals files for merger – releases further details about license agreement with NeuroVive
NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, is able to present further details regarding the previously communicated exclusive, worldwide licensing agreement with OnCore Biop ...
Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B
US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive's drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with ...
Annual General Meeting brought forward to March 30 2015
The Board of NeuroVive Pharmaceutical AB (publ) has decided to bring forward the Annual General Meeting 2015 to Monday 30 March, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden to ...
NeuroVive employs a Clinical Trial Manager
NeuroVive Pharmaceutical AB (publ) has recruited Gunilla Lindgren to the position as Clinical Trial Manager. The recruitment enables NeuroVive to ensure the sustained high quality and efficient operat ...
NeuroVive and Skåne University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has initiated a collaboration with Skåne University Hospital to complete a clinical phase II study on the evaluation of the comp ...
Annual General Meeting 2015 and information about members appointed to the Nomination Committee
The Annual General Meeting in NeuroVive Pharmaceutical AB (publ) will be held on Wednesday 29 April, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.
Addendum: OnCore License
At the request of NASDAQ OMX Stockholm, the Company provides the following information regarding the license agreement referred to in the press release dated September 9, 2014.
NeuroVive signs USD 150 m agreement with OnCore BioPharma for the outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection
NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicensing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the deve ...
Enrollment to phase II study on NeuroSTAT® continues
Enrollment to the ongoing clinical phase IIa study with NeuroVive's drug candidate NeuroSTAT® for treating patients with severe traumatic brain injury (TBI) is continuing, and another two patients hav ...
NeuroVive’s research into energy regulation wins award at international research symposium
NeuroVive, a leading mitochondrial medicine company, participated in the international research symposium Mitochondrial Medicine 2014 held in Pittsburgh, USA, on 4-7 June. NeuroVive presented research ...